Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2011 1
2012 2
2013 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma.
Ter Maat LS, van Duin IAJ, Elias SG, Leiner T, Verhoeff JJC, Arntz ERAN, Troenokarso MF, Blokx WAM, Isgum I, de Wit GA, van den Berkmortel FWPJ, Boers-Sonderen MJ, Boomsma MF, van den Eertwegh FJM, de Groot JWB, Piersma D, Vreugdenhil A, Westgeest HM, Kapiteijn E, van Diest PJ, Pluim JPW, de Jong PA, Suijkerbuijk KPM, Veta M. Ter Maat LS, et al. Among authors: van den eertwegh fjm. Eur J Cancer. 2023 May;185:167-177. doi: 10.1016/j.ejca.2023.02.017. Epub 2023 Feb 24. Eur J Cancer. 2023. PMID: 36996627 Free article.
High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry.
Westgeest HM, Kuppen MCP, van den Eertwegh FAJM, van Oort IM, Coenen JLLM, van Moorselaar JRJA, Aben KKH, Bergman AM, Huinink DTB, van den Bosch J, Hendriks MP, Lampe MI, Lavalaye J, Mehra N, Smilde TJ, Somford RDM, Tick L, Weijl NI, van de Wouw YAJ, Gerritsen WR, Groot CAU. Westgeest HM, et al. Among authors: van den eertwegh fajm. J Palliat Med. 2021 Dec;24(12):1789-1797. doi: 10.1089/jpm.2020.0800. Epub 2021 Aug 19. J Palliat Med. 2021. PMID: 34415798
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group. Motzer RJ, et al. Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22. Lancet. 2008. PMID: 18653228 Clinical Trial.
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group. Grünwald V, et al. Eur J Cancer. 2012 Feb;48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29. Eur J Cancer. 2012. PMID: 21803569 Clinical Trial.